ST. LOUIS (March 26, 2013) – RiverVest Venture Partners’ Principal Niall O’Donnell, Ph.D., has been invited to serve on the Experts Panel at Stevenage Bioscience Catalyst, the U.K.’s first open innovation bioscience campus focused on driving early-stage biotech, pharma and medtech developments.
SAN DIEGO, March 20, 2013 /PRNewswire-USNewswire/ — The Rady School of Management’s student-run venture capital fund, the Rady Venture Fund, has participated in a $16 million Series B raise in startup Savara Pharmaceuticals, which is developing an inhalable antibiotic to treat cystic fibrosis patients with lung infections.
ST. LOUIS (March 12, 2013) – RiverVest Venture Partners announced today that its Fund II has delivered a return of more than double that of a respected benchmark that delineates top-performing venture capital funds.
Rivervest’s Karen Spilizewski is scheduled to join other entrepreneurial luminaries when she speaks at the 2012 National Association for Seed and Venture Funds (NASVF) Conference. Keynote speakers include Steve Case, TechStars’ Katie Rae and Open Table’s Chuck Templeton, who are all scheduled to address this year’s theme: “Advancing Innovation: Seeding Tomorrow’s Opportunities.”
Once a major headquarters town, the Gateway City is becoming more entrepreneurial….Read More
May 5, 2012 – William A. Peck, MD, the Alan A. and Edith L. Wolff Distinguished Professor of Medicine and director of the Center for Health Policy at Washington University in St. Louis, was presented with the Washington University Eliot Society “Search” Award at the 45th annual dinner of the William Greenleaf Eliot Society May […]
March 16, 2012 – A $1 billion-plus deal between Boston Scientific Corp. and medical device firm Cameron Health Inc. is bringing a payout of more than $12 million to RiverVest Venture Partners and its investors. Read More
RiverVest Venture Partners today announced that Boston Scientific Corporation has exercised its option to acquire RiverVest portfolio company Cameron Health, Inc., a medical device innovator based in San Clemente, California.
This is RiverVest’s 4th exit in its Fund II portfolio.
RiverVest Venture Partners today announced that RiverVest V.P. Karen Spilizewski will speak at BioMEMS 2012’s Venture Capital session on March 22.
The conference will focus on MEMS technologies for biomedical applications, or BioMEMS, whose market size is estimated at $1.7 billion.
Thomas Melzer is named to the 2012 Class of Most Influential St. Louisans. Read More
February 14, 2012 – Neurostimulation startup Neuros Medical, which is developing a device to block the chronic pain of amputees, has secured a new investor in RiverVest Venture Partners. Read More
RiverVest Venture Partners today announced that it successfully sold four life science companies for more than $1 billion, generated upfront returns of up to five times the initial investment, and beat industry benchmarks.
“RiverVest has really separated itself from the pack,” says Boston-based investor John F. Brooke, who manages the Vectis Healthcare & Life Sciences Fund, which is an investor in RiverVest Venture Partners Fund II, L.P.